93 related articles for article (PubMed ID: 12106594)
1. Monitoring the correction of glycogen storage disease type 1a in a mouse model using [(18)F]FDG and a dedicated animal scanner.
Zingone A; Seidel J; Aloj L; Caraco C; Vaquero JJ; Jagoda EM; Chou JY; Green MV; Eckelman WC
Life Sci; 2002 Aug; 71(11):1293-301. PubMed ID: 12106594
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.
Chou JY; Zingone A; Pan CJ
Eur J Pediatr; 2002 Oct; 161 Suppl 1():S56-61. PubMed ID: 12373573
[TBL] [Abstract][Full Text] [Related]
3. Correction of glycogen storage disease type 1a in a mouse model by gene therapy.
Zingone A; Hiraiwa H; Pan CJ; Lin B; Chen H; Ward JM; Chou JY
J Biol Chem; 2000 Jan; 275(2):828-32. PubMed ID: 10625614
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
[TBL] [Abstract][Full Text] [Related]
5. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
[TBL] [Abstract][Full Text] [Related]
6. Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice.
Clar J; Mutel E; Gri B; Creneguy A; Stefanutti A; Gaillard S; Ferry N; Beuf O; Mithieux G; Nguyen TH; Rajas F
Hum Mol Genet; 2015 Apr; 24(8):2287-96. PubMed ID: 25561689
[TBL] [Abstract][Full Text] [Related]
7. Glucose-6-phosphatase Expression-Mediated [
Kim MJ; Lee CH; Lee Y; Youn H; Kang KW; Kwon J; Alavi A; Carlin S; Cheon GJ; Chung JK
Mol Imaging Biol; 2019 Oct; 21(5):917-925. PubMed ID: 30719695
[TBL] [Abstract][Full Text] [Related]
8. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
[TBL] [Abstract][Full Text] [Related]
9. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.
Landau DJ; Brooks ED; Perez-Pinera P; Amarasekara H; Mefferd A; Li S; Bird A; Gersbach CA; Koeberl DD
Mol Ther; 2016 Apr; 24(4):697-706. PubMed ID: 26865405
[TBL] [Abstract][Full Text] [Related]
11. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
[TBL] [Abstract][Full Text] [Related]
12. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
[TBL] [Abstract][Full Text] [Related]
13. A detailed characterization of the adult mouse model of glycogen storage disease Ia.
Salganik SV; Weinstein DA; Shupe TD; Salganik M; Pintilie DG; Petersen BE
Lab Invest; 2009 Sep; 89(9):1032-42. PubMed ID: 19581879
[TBL] [Abstract][Full Text] [Related]
14. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse.
Lei KJ; Chen H; Pan CJ; Ward JM; Mosinger B; Lee EJ; Westphal H; Mansfield BC; Chou JY
Nat Genet; 1996 Jun; 13(2):203-9. PubMed ID: 8640227
[TBL] [Abstract][Full Text] [Related]
15. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
16. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
[TBL] [Abstract][Full Text] [Related]
17. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
[TBL] [Abstract][Full Text] [Related]
18. Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.
Grinshpun A; Condiotti R; Waddington SN; Peer M; Zeig E; Peretz S; Simerzin A; Chou J; Pann CJ; Giladi H; Galun E
Mol Ther; 2010 Sep; 18(9):1592-8. PubMed ID: 20571544
[TBL] [Abstract][Full Text] [Related]
19. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
20. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas.
Mutel E; Abdul-Wahed A; Ramamonjisoa N; Stefanutti A; Houberdon I; Cavassila S; Pilleul F; Beuf O; Gautier-Stein A; Penhoat A; Mithieux G; Rajas F
J Hepatol; 2011 Mar; 54(3):529-37. PubMed ID: 21109326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
